ERBB2 and triple-negative breast carcinoma: Favourable long-term oncological outcomes have been associated with a pCR at surgery, particularly in patients with triple-negative breast cancer (TNBC) and human epidermal growth factor receptor 2 (HER2)-positive tumours2,3.